Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder - Full Text View

Sponsors and Collaborators:	University of Utah National Cancer Institute (NCI)
Information provided by:	University of Utah
ClinicalTrials.gov Identifier:	NCT00722254

Purpose

To determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension, and to discover if the fibrosis in these patients is primary (AMM) or secondary.

Condition
Primary Myelofibrosis Primary Pulmonary Hypertension Secondary Myelofibrosis Pulmonary Arterial Hypertension

Genetics Home Reference related topics: pulmonary arterial hypertension

MedlinePlus related topics: High Blood Pressure Pulmonary Hypertension Spleen Diseases

Drug Information available for: Epoprostenol Epoprostenol sodium

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

Further study details as provided by University of Utah:

Primary Outcome Measures:

Determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension [ Time Frame: After sample is obtained ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Discover if the fibrosis in patients with primary pulmonary hypertension is primary (AMM) or secondary. [ Time Frame: After sample is obtained ] [ Designated as safety issue: No ]
Clonality [ Time Frame: After sample is obtained ] [ Designated as safety issue: No ]

Biospecimen Retention: Samples With DNA

Biospecimen Description:

Whole Blood

Estimated Enrollment:	60
Study Start Date:	June 2006
Estimated Study Completion Date:	March 2010
Estimated Primary Completion Date:	March 2010 (Final data collection date for primary outcome measure)

Groups/Cohorts
PPH Subjects diagnosed with primary pulmonary hypertension (PPH)
Myelofibrosis Subjects diagnosed with Primary or Secondary Myelofibrosis

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients suffering from primary pulmonary hypertension or myelofibrosis (primary or secondary)

Criteria

Inclusion Criteria:

> 18 years of age
Signed Informed Consent
Subjects diagnosed with Primary Pulmonary Hypertension or Myelofibrosis (primary or secondary)

Exclusion Criteria:

Anyone not meeting the above inclusion criteria
Pregnant women

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00722254

Contacts

Contact: Josef T Prchal, MD	801-581-4220	josef.prchal@hsc.utah.edu
Contact: Kim Hickman, BS	801-581-3707	kimberly.hickman@hsc.utah.edu

Locations

United States, Utah
University of Utah	Recruiting
Salt Lake City, Utah, United States, 84132
Contact: Josef T Prchal, MD 801-581-4220 josef.prchal@hsc.utah.edu
Contact: Kim Hickman, BS 801-581-3707 kimberly.hickman@hsc.utah.edu
Principal Investigator: Josef T Prchal, MD
Sub-Investigator: Charles Parker, MD
Sub-Investigator: Scott Samuelson, MD
Sub-Investigator: Neeraj Agarwal, MD
Sub-Investigator: Andrew Chen, MD
Sub-Investigator: Mohamed Salama, MD
Sub-Investigator: Archana Agarwal, MD
Sub-Investigator: Todd Kelley, MD
VA Salt Lake City Health Care System	Recruiting
Salt lake City, Utah, United States, 84148
Contact: Josef T Prchal, MD 801-581-3707 josef.prchal@hsc.utah.edu
Contact: Kim Hickman, BS 801-581-3707 kimberly.hickman@hsc.utah.edu

Sponsors and Collaborators

University of Utah

National Cancer Institute (NCI)

Investigators

Principal Investigator:

Josef T Prchal, MD

University of Utah

More Information

Publications:

Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant. 2007 Jan;13(1 Suppl 1):64-72. Review.

Chen GL, Liu E, Naidoo K, Popat U, Coetzer TL, Prchal JT. Idiopathic myelofibrosis without dacryocytes. Haematologica. 2006 Jun;91(6 Suppl):ECR29.

Popat U, Frost A, Liu E, Guan Y, Durette A, Reddy V, Prchal JT. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood. 2006 May 1;107(9):3486-8. Epub 2006 Jan 17.

Popat U, Frost A, Liu E, May R, Bag R, Reddy V, Prchal JT. New onset of myelofibrosis in association with pulmonary arterial hypertension. Ann Intern Med. 2005 Sep 20;143(6):466-7. No abstract available.

Xu M, Bruno E, Chao J, Huang S, Finazzi G, Fruchtman SM, Popat U, Prchal JT, Barosi G, Hoffman R; MPD Research Consortium. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood. 2005 Jun 1;105(11):4508-15. Epub 2005 Feb 10.

Phelan JT 2nd, Prchal JT. Clonality studies in cancer based on X chromosome inactivation phenomenon. Methods Mol Med. 2002;68:251-70. No abstract available.

Damps-Konstańska I, Konstański Z, Jassem E. [Treatment of pulmonary hypertension] Wiad Lek. 2007;60(11-12):545-9. Polish.

Cortelezzi A, Gritti G, Del Papa N, Pasquini MC, Calori R, Gianelli U, Cortiana M, Parati G, Onida F, Sozzi F, Vener C, Bianchi P, Deliliers GL. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia. 2008 Mar;22(3):646-9. Epub 2007 Sep 13. No abstract available.

Halank M, Marx C, Baretton G, Müller KM, Ehninger G, Höffken G. Severe pulmonary hypertension in chronic idiopathic myelofibrosis. Onkologie. 2004 Oct;27(5):472-4.

Responsible Party:	University of Utah ( Josef T. Prchal, MD )
Study ID Numbers:	17806
Study First Received:	July 23, 2008
Last Updated:	July 23, 2008
ClinicalTrials.gov Identifier:	NCT00722254
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Utah:

Myeloproliferative Disorder
Primary Myelofibrosis
Primary Pulmonary Hypertension
Secondary Myelofibrosis
Pulmonary Arterial Hypertension

Flolan
Clonality
CD34+ cells
Hematologic abnormalities

Study placed in the following topic categories:

Idiopathic pulmonary hypertension
Myelofibrosis
Hematologic Diseases
Vascular Diseases
Myeloproliferative Disorders
Myeloid Metaplasia
Myelofibrosis-osteosclerosis
Lymphatic Diseases
Respiratory Tract Diseases

Hypertension, Pulmonary
Metaplasia
Lung Diseases
Epoprostenol
Neoplasm Metastasis
Congenital Abnormalities
Bone Marrow Diseases
Hypertension

Additional relevant MeSH terms:

Neoplasms
Neoplastic Processes
Pathologic Processes
Cardiovascular Diseases
Splenic Diseases

ClinicalTrials.gov processed this record on January 16, 2009